Hassana el Haddaoui

Mrs. Hassana el Haddaoui

Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HHHassana el Haddaoui
Hassana el Haddaoui
RBRianne Brood
Rianne Brood
DLDiba Latifi
Diba Latifi
AOAstrid A. Oostvogels
Astrid A. Oostvogels
YKYarne Klaver
Yarne Klaver
Casper Van EijckCasper Van Eijck
Casper Van Eijck
Background: Treatment with the TLR-3 agonist rintatolimod may improve pancreatic cancer patients’ survival via immunomodulation, but the effect is unproven. Methods: In this single-center named patient program, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated with rintatolimod (six weeks total, twice per week, with a maximum of 400 mg per infusion). The primary endpoints were the systemic immune-inflammation index (SIII), the neutrophil to lymphocyte ratio (NLR), and the absolute counts of 18 different populations of circulating immune cells as measured by flow cytometry. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Subgroup analyses were performed in long-term survivors (>1-year overall survival after starting rintatolimod) and compared to short-term survivors (≤1 year). Results: Between January 2017 and February 2019, twenty-seven patients with stable LAPC or metastatic disease were pre-treated with FOLFIRINOX and treated with rintatolimod. Rintatolimod treatment was well-tolerated. The SIII and NLR values were significantly lower in the 11 long-term survivors, versus 16 short-term survivors. The numbers of B-cells were significantly increased in long-term survivors. Numbers of T cells and myeloid cells were not significantly increased after treatment with rintatolimod. Median PFS was 13 months with rintatolimod, versus 8.6 months in a subset of matched controls (n = 27, hazard ratio = 0.52, 95% CI = 0.28–0.90, p = 0.007). The median OS was 19 months with rintatolimod, versus 12.5 months in the matched control (hazard ratio = 0.51, 95% CI = 0.28–0.90, p = 0.016). Conclusions: Treatment with rintatolimod showed a favorable effect on the numbers of peripheral B cells in patients with pancreatic cancer and improved survival in pancreatic cancer, but additional evidence is required.

15 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Casper Van EijckCasper Van Eijck
Casper Van Eijck
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
MWMarcella Willemsen
Marcella Willemsen
Purpose: Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC. Experimental Design: Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models. Results: Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1. Conclusions: This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes. See related commentary by Martínez-Riaño et al., p. 3355

1 July 2020 in Cytokine
Verified
Journal Article
Closed access
RRRachida Rafiq
Rachida Rafiq
HHHassana el Haddaoui
Hassana el Haddaoui
RMRenée de Mutsert
Renée de Mutsert
FRFrits R. Rosendaal
Frits R. Rosendaal
PHPieter Hiemstra
Pieter Hiemstra
RJRenate T. de Jongh
Renate T. de Jongh

15 August 2024
Verified
Other
Open access
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Purpose:Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.Experimental Design:Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.Results:Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.Conclusions:This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

15 August 2024
Verified
Other
Open access
PDF file
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Supplementary Figure S3. Transcriptomic NanoString analysis for delta values (after mRNA counts – baseline mRNA counts). (A) t-SNE plot illustrates no apparent segregation of delta changes among 730 immune-related genes based on treatment response. (B) Boxplots displaying significant DE genes between stable and progressive disease patients upon rintatolimod treatment. The x-axis represents different genes, and the y-axis represents the log2 gene expression count.

15 August 2024
Verified
Other
Open access
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Purpose:Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.Experimental Design:Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.Results:Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.Conclusions:This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355